Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes
- 31 May 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 16 (7) , 833-843
Abstract
Linezolid inhibits bacterial growth by targeting bacterial ribosomes and by interfering with bacterial protein synthesis. Lactic acidosis is a rare, but potentially lethal, side effect of linezolid. Areas covered: The pathogenesis of linezolid-induced lactic acidosis is reviewed with special emphasis on aspects relevant to the recognition, prevention and treatment of the syndrome. Expert opinion: Linezolid-induced lactic acidosis reflects the untoward interaction between the drug and mitochondrial ribosomes. The inhibition of mitochondrial protein synthesis diminishes the respiratory chain enzyme content and thus limits aerobic energy production. As a result, anaerobic glycolysis and lactate generation accelerate independently from tissue hypoxia. In the absence of any confirmatory test, linezolid-induced lactic acidosis should be suspected only after exclusion of other, more common, causes of lactic acidosis such as hypoxemia, anemia or low cardiac output. Normal-to-high whole-body oxygen delivery, high venous oxygen saturation and lack of response to interventions that effectively increase tissue oxygen provision all suggest a primary defect in oxygen use at the mitochondrial level. During prolonged therapy with linezolid, blood drug and lactate levels should be regularly monitored. The current standard-of-care treatment of linezolid-induced lactic acidosis consists of drug withdrawal to reverse mitochondrial intoxication and intercurrent life support.Keywords
This publication has 95 references indexed in Scilit:
- Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic indexExpert Review of Anti-infective Therapy, 2016
- Incidence and risk factors of linezolid-induced lactic acidosisInternational Journal of Infectious Diseases, 2015
- Clinical experience with linezolid for the treatment of orthopaedic implant infectionsJournal of Antimicrobial Chemotherapy, 2014
- Public health need versus sales of antibacterial agents active against multidrug-resistant bacteria: a historical perspectiveJournal of Antimicrobial Chemotherapy, 2013
- Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patientsJournal of Antimicrobial Chemotherapy, 2012
- Linezolid for the treatment of adults with bone and joint infectionsInternational Journal of Antimicrobial Agents, 2007
- Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex PatientsAntimicrobial Agents and Chemotherapy, 2006
- Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III StudiesAntimicrobial Agents and Chemotherapy, 2003
- Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone AntibacterialClinical Pharmacokinetics, 2003
- Oxazolidinone antibioticsThe Lancet, 2001